ArticleDiscover oncology2025
An extremely rare case of thymic carcinoma manifesting as a liver metastasis: a case report and literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic carcinoma is a rare and aggressive malignancy originating from thymic epithelial cells. We report a case of a 59-year-old male who presented with a progressively enlarging abdominal mass. Physical examination revealed a firm epigastric mass and supraclavicular lymphadenopathy. Chest radiography demonstrated right lower lung consolidation with nodules and left lower lobe infiltrates. Laboratory investigations showed elevated levels of CEA, AFP, LDH, CYFRA 21-1, and PSA. Contrast-enhanced abdominal CT revealed multiple heterogeneous hepatic lesions, the largest measuring 8.7 × 7.4 × 10.8 cm, along with an enhancing right adrenal nodule, suggestive of metastatic disease. Liver biopsy demonstrated a malignant small round blue cell tumor. Initial immunohistochemical analysis showed strong CD117 positivity with negative CK7, LCA, desmin, and S100, initially suggestive of gastrointestinal stromal tumor (GIST), for which imatinib therapy was initiated. However, due to disease progression, a cervical lymph node biopsy was performed, revealing poorly differentiated carcinoma with positive staining for p63 and CD117. Re-evaluation of the initial liver biopsy, supplemented by additional immunohistochemical profiling (p63 and p40 positivity), led to a revised diagnosis of thymic carcinoma, squamous cell carcinoma subtype, with hepatic and nodal metastases. This case highlights the diagnostic complexity of thymic carcinoma with atypical metastatic presentation and underscores the critical role of iterative histopathological evaluation and multidisciplinary collaboration in the management of rare malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.